Top-Rated StocksTop-RatedNASDAQ:NTRA Natera (NTRA) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free NTRA Stock Alerts $91.46 +1.00 (+1.11%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$89.20▼$92.4250-Day Range$64.62▼$92.9052-Week Range$36.90▼$96.24Volume971,264 shsAverage Volume1.78 million shsMarket Capitalization$11.04 billionP/E RatioN/ADividend YieldN/APrice Target$78.36 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Natera alerts: Email Address Natera MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside14.3% Downside$78.36 Price TargetShort InterestHealthy6.58% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.08Based on 7 Articles This WeekInsider TradingSelling Shares$25.98 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.43) to ($1.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.06 out of 5 starsMedical Sector678th out of 938 stocksMedical Laboratories Industry15th out of 20 stocks 2.5 Analyst's Opinion Consensus RatingNatera has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $78.36, Natera has a forecasted downside of 14.3% from its current price of $91.46.Amount of Analyst CoverageNatera has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.58% of the outstanding shares of Natera have been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Natera has recently decreased by 7.02%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNatera does not currently pay a dividend.Dividend GrowthNatera does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NTRA. Previous Next 3.9 News and Social Media Coverage News SentimentNatera has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Natera this week, compared to 5 articles on an average week.Search Interest33 people have searched for NTRA on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.MarketBeat Follows16 people have added Natera to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,979,705.00 in company stock.Percentage Held by InsidersOnly 9.42% of the stock of Natera is held by insiders.Percentage Held by Institutions99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Natera are expected to grow in the coming year, from ($2.43) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Natera is -24.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Natera is -24.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNatera has a P/B Ratio of 14.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Natera Stock (NASDAQ:NTRA)Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Read More NTRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NTRA Stock News HeadlinesMarch 17, 2024 | insidertrades.comNatera, Inc. (NASDAQ:NTRA) Chairman Matthew Rabinowitz Sells 1,012 SharesMarch 17, 2024 | insidertrades.comSteven Leonard Chapman Sells 83,223 Shares of Natera, Inc. (NASDAQ:NTRA) StockMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 29, 2024 | americanbankingnews.comNatera, Inc. (NASDAQ:NTRA) Receives Average Rating of "Moderate Buy" from AnalystsMarch 23, 2024 | americanbankingnews.comNatera (NASDAQ:NTRA) Hits New 52-Week High at $96.24March 22, 2024 | seekingalpha.comNatera: Capitalizing On The Positive Momentum Of Personalized MedicineMarch 20, 2024 | finance.yahoo.comWill Natera (NTRA) Continue to Deliver Solid Topline Growth?March 18, 2024 | msn.comGenetic Testing Stock Nears Buy Point After Earnings Gap Up And 45% GainMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 18, 2024 | stockhouse.comNatera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera(TM) in Stage II Colorectal CancerMarch 18, 2024 | finance.yahoo.comNatera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal CancerMarch 16, 2024 | finance.yahoo.comNTRA Apr 2024 90.000 putMarch 16, 2024 | finance.yahoo.comNTRA Apr 2024 87.500 callMarch 16, 2024 | finance.yahoo.comNTRA Apr 2024 80.000 putMarch 15, 2024 | finance.yahoo.comNTRA Mar 2024 82.500 callMarch 14, 2024 | finance.yahoo.comNew KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of DiseaseMarch 12, 2024 | finance.yahoo.comNatera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast CancersMarch 12, 2024 | businesswire.comNatera to Present New Data at the 2024 SGO Annual Meeting on Women's Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast CancersMarch 10, 2024 | finance.yahoo.comNTRA Oct 2024 97.500 callMarch 8, 2024 | finance.yahoo.comSEC and Chief Legal Officer Daniel Rabinowitz Sells Shares of Natera Inc (NTRA)March 7, 2024 | businesswire.comNatera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS PlanMarch 2, 2024 | finance.yahoo.comNatera Full Year 2023 Earnings: Beats ExpectationsMarch 1, 2024 | markets.businessinsider.comNatera’s Strong Q4 Performance and Positive Outlook Merit Buy Rating and $90 Price TargetMarch 1, 2024 | finance.yahoo.comDecoding Natera Inc (NTRA): A Strategic SWOT InsightFebruary 29, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Jazz Pharmaceuticals (JAZZ) and Natera (NTRA)February 29, 2024 | markets.businessinsider.comNatera’s Strong Q4 Performance and Market Positioning Warrant a Buy Rating with Increased Price TargetFebruary 29, 2024 | finance.yahoo.comNatera to Participate in March Investor ConferencesSee More Headlines Receive NTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:NTRA CUSIPN/A CIK1604821 Webwww.natera.com Phone(650) 249-9090FaxN/AEmployees3,293Year FoundedN/APrice Target and Rating Average Stock Price Target$78.36 High Stock Price Target$110.00 Low Stock Price Target$48.00 Potential Upside/Downside-14.3%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($3.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-434,800,000.00 Net Margins-40.16% Pretax Margin-40.14% Return on Equity-62.19% Return on Assets-31.88% Debt Debt-to-Equity Ratio0.37 Current Ratio4.10 Quick Ratio3.96 Sales & Book Value Annual Sales$1.08 billion Price / Sales10.20 Cash FlowN/A Price / Cash FlowN/A Book Value$6.37 per share Price / Book14.36Miscellaneous Outstanding Shares120,760,000Free Float109,383,000Market Cap$11.04 billion OptionableOptionable Beta1.39 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Matthew Rabinowitz Ph.D. (Age 51)Co-Founder & Executive Chairman Comp: $441.58kMr. Steven Leonard Chapman (Age 45)CEO & Director Comp: $1.15MMr. Michael B. Brophy M.B.A. (Age 44)Chief Financial Officer Comp: $611.35kMr. Daniel Rabinowitz L.L.M. (Age 55)Secretary & Chief Legal Officer Comp: $566.03kMr. John FeskoPresident & Chief Business OfficerMr. Jonathan Sheena M.Eng. (Age 51)Co-Founder & Director Comp: $293.91kMs. Olesya A. Anisimova CPAChief Accounting OfficerMr. Rishi KackerChief Technology OfficerMr. Eric A. EvansChief Scientific OfficerMr. Jerry DiffleyChief Compliance & Privacy OfficerMore ExecutivesKey CompetitorsExact SciencesNASDAQ:EXASQuest DiagnosticsNYSE:DGXLaboratory Co. of AmericaNYSE:LHFortreaNASDAQ:FTRERadNetNASDAQ:RDNTView All CompetitorsInsiders & InstitutionsHealthcare of Ontario Pension Plan Trust FundBought 40,928 shares on 3/21/2024Ownership: 0.039%Steven Leonard ChapmanSold 83,223 sharesTotal: $7.40 M ($88.96/share)Vanguard Group Inc.Bought 588,147 shares on 3/11/2024Ownership: 9.086%Matthew RabinowitzSold 1,012 sharesTotal: $89,420.32 ($88.36/share)Jonathan SheenaSold 1,028 sharesTotal: $90,834.08 ($88.36/share)View All Insider TransactionsView All Institutional Transactions NTRA Stock Analysis - Frequently Asked Questions Should I buy or sell Natera stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NTRA shares. View NTRA analyst ratings or view top-rated stocks. What is Natera's stock price target for 2024? 13 brokers have issued 12-month target prices for Natera's shares. Their NTRA share price targets range from $48.00 to $110.00. On average, they anticipate the company's share price to reach $78.36 in the next twelve months. This suggests that the stock has a possible downside of 14.3%. View analysts price targets for NTRA or view top-rated stocks among Wall Street analysts. How have NTRA shares performed in 2024? Natera's stock was trading at $62.64 on January 1st, 2024. Since then, NTRA stock has increased by 46.0% and is now trading at $91.46. View the best growth stocks for 2024 here. When is Natera's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our NTRA earnings forecast. How were Natera's earnings last quarter? Natera, Inc. (NASDAQ:NTRA) released its quarterly earnings results on Wednesday, February, 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.09. The medical research company had revenue of $311.11 million for the quarter, compared to analysts' expectations of $300.38 million. Natera had a negative net margin of 40.16% and a negative trailing twelve-month return on equity of 62.19%. What ETFs hold Natera's stock? ETFs with the largest weight of Natera (NASDAQ:NTRA) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Alger 35 ETF (ATFV), Alger Mid Cap 40 ETF (FRTY), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Health Care AlphaDEX Fund (FXH), Principal Healthcare Innovators ETF (BTEC) and VanEck Biotech ETF (BBH). What guidance has Natera issued on next quarter's earnings? Natera issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion. What is Steve Chapman's approval rating as Natera's CEO? 158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN). When did Natera IPO? Natera (NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. Who are Natera's major shareholders? Natera's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.13%), Vanguard Group Inc. (9.09%), RTW Investments LP (2.16%), Kynam Capital Management LP (2.00%), Principal Financial Group Inc. (1.42%) and Norges Bank (1.12%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, John Fesko, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens. View institutional ownership trends. How do I buy shares of Natera? Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NTRA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Natera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.